Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Taro Pharmaceutical Industries Ltd.
Taro to Launch Oxcarbazepine in the United States
January 25th, 2008
Taro Pharmaceutical Industries Ltd. ("Taro," Pink Sheets: TAROF) reported that it settled a pending lawsuit with Novartis and will be launching Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg ("Oxcarbazepine Tablets") in the United States. Oxcarbazepine Tablets, marketed by Novartis as Trileptal(R) Tablets, is a prescription pharmaceutical product used in treating seizures. Taro recently settled litigation with Novartis regarding Taro's "Paragraph IV" certification challenging Novartis' patent protection on Trileptal(R). On November 15, 2007, Taro received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Oxcarbazepine...
Source: Medical Patent Business Week (2008-01-25)
|
